Skip to main content
    D

    Dianthus Therapeutics Inc. (DNTH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $74.53
    -0.23 (-0.31%)

    Market Cap: $4.18B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(18/33)
    Avg Surprise
    -19.63%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.95
    Range$-1.13 - $-0.39
    10 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.02+7.2%
    60d ago$-1.02+7.2%
    30d ago$-1.02+7.0%
    7d ago$-0.950.0%
    Current$-0.95
    Revenue Consensus
    $366420
    Range$0 - $1M
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.85
    Range$-1.14 - $-0.47
    11 analysts
    Revenue Consensus
    $896000
    Range$-73860 - $2M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.85---
    Sep 26EST
    		-$-0.95---
    Jun 26
    Reported Aug 4
    		$-0.90$-0.93+3.23%Beat-2.3%
    Mar 26
    Reported May 5
    		$-0.85$-1.10+22.73%Beat-3.7%
    Dec 25
    Reported Mar 9
    		$-1.43$-1.03-38.65%Miss-76.5%
    Sep 25
    Reported Nov 5
    		$-0.97$-0.86-12.79%Miss-31.1%
    Jun 25
    Reported Aug 7
    		$-0.88$-0.86-2.33%Miss-72.5%
    Mar 25
    Reported May 12
    		$-0.82$-0.71-15.49%Miss-51.9%
    Dec 24
    Reported Mar 11
    		$-0.81$-0.76-6.58%Miss-14.1%
    Sep 24
    Reported Nov 7
    		$-0.74$-0.60-23.33%Miss+80.4%
    Jun 24
    Reported Aug 8
    		$-0.51$-0.55+7.27%Beat+41.1%
    Mar 24
    Reported May 9
    		$-0.54$-0.44-22.73%Miss-14.9%
    Dec 23
    Reported Mar 21
    		$-0.71$-1.01+29.70%Beat-136.7%
    Sep 23
    Reported Nov 9
    		$-3.78$-0.56-575.00%Miss-1300.0%
    Jun 23
    Reported Aug 3
    		$-0.87N/A+71.50%Beat-198.7%
    Mar 23
    Reported May 11
    		$-0.47$-0.40-17.50%Miss-20.5%
    Dec 22
    Reported Mar 29
    		$-0.30$-0.28-8.62%Miss+9.1%
    Sep 22
    Reported Nov 3
    		$-0.27$-0.29+6.90%Beat+10.0%
    Jun 22
    Reported Aug 4
    		$-0.29$-0.34+14.71%Beat+9.4%
    Mar 22
    Reported May 16
    		$-0.39$-0.32-22.60%Miss-8.3%
    Dec 21
    Reported Mar 8
    		$-0.33$-0.32-4.13%Miss+13.2%
    Sep 21
    Reported Nov 4
    		$-0.30$-0.33+8.68%Beat+18.9%
    Jun 21
    Reported Aug 5
    		$-0.32$-0.37+14.09%Beat+33.3%
    Mar 21
    Reported May 6
    		$-0.36$-0.39+7.22%Beat+29.4%
    Dec 20
    Reported Mar 3
    		$-0.38$-0.39+2.06%Beat+35.6%
    Sep 20
    Reported Nov 5
    		$-0.37$-0.43+13.95%Beat+31.5%
    Jun 20
    Reported Aug 6
    		$-0.48$-0.54+11.11%Beat+0.0%
    Mar 20
    Reported May 7
    		$-0.51$-0.60+15.00%Beat-15.9%
    Dec 19
    Reported Mar 3
    		$-0.59$-0.58-1.72%Miss-18.0%
    Sep 19
    Reported Nov 13
    		$-0.54$-0.53-1.89%Miss-10.2%
    Jun 19
    Reported Aug 8
    		$-0.48$-0.49+2.04%Beat+84.7%
    Mar 19
    Reported May 9
    		$-0.44$-0.55+20.00%Beat+90.1%
    Dec 18
    Reported Mar 19
    		$-0.50$-0.53+5.66%Beat+51.5%
    Sep 18
    Reported Nov 8
    		$-0.49$-0.67+26.87%Beat-226.7%
    Jun 18
    Reported Aug 9
    		$-3.13$-1.13-176.99%Miss-
    Mar 18
    Reported May 30
    		$-4.45$0.00N/AMiss-
    Dec 17
    Reported Mar 30
    		$-1.03$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-17.96EV/EBITDAN/A
    Price/FCF-26.82xFCF Yield-3.73%
    Profitability
    Profit Margin0.00%Operating Margin-8079.00%
    ROE-26.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio26.10xQuick Ratio26.10x
    Trading Statistics
    Beta0.18Avg Volume1.00M
    52-Week High$117.8852-Week Low$32.22

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$81.98
    SMA 20$86.77
    SMA 50$100.07
    SMA 200$82.90
    EMA 10$81.08
    EMA 20$86.45
    EMA 50$93.98
    EMA 200$82.69

    MACD

    Line: -6.63Signal: -5.75Hist: -0.89

    ADX

    ADX: 46.8+DI: 6.5-DI: 37.7

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$81.50

    Bollinger Bands

    Upper Band$100.15
    Lower Band$73.39
    %B Position3084%(Upper)
    Band Width0.04

    RSI (14-Day)

    Oversold
    16.2

    Momentum Oscillators

    Stoch %K4.5
    Stoch %D3.7
    Williams %R-90.0
    ROC (10d)-15.6%
    Momentum-13.79
    CCI (20d)-161.8
    MFI (14d)27.4

    Volatility Measures

    ATR (14d)$4.30(5.8%)
    StdDev (20d)6.69
    Hist Vol31.5%(Moderate)

    Volume Flow

    VWAP$74.92
    OBV30.4M
    AD Line2.7M
    CMF (20d)-0.464

    Volume Metrics

    Avg Vol (20d)995.1K
    Vol Ratio0.9x
    VWMA (20d)$87.64

    Pivot Points

    R3$81.85
    R2$80.31
    R1$77.54
    Pivot Point$76.00
    S1$73.23
    S2$71.69
    S3$68.92

    Advanced Oscillators

    TSI-53.86
    Ultimate Osc25.1
    KST-210.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$761,000$0$873,000$0$0$1.16M$1.33M$2.17M$1.86M$874,000$457,000$924,000
    Cost of Revenue$0$0N/A$0$0$0$78,000$0$0$0$103,000$0
    Gross Profit$761,000$0$873,000$0$0$1.16M$1.33M$2.17M$1.86M$874,000$457,000$924,000
    Operating Expenses$62.24M$47.00M$69.83M$40.68M$35.12M$34.34M$33.24M$32.07M$24.07M$18.72M$13.41M$16.68M
    R&D$48.69M$34.53M$59.90M$32.49M$26.25M$27.00M$26.41M$25.54M$18.07M$13.08M$8.78M$7.96M
    SG&A$13.56M$12.47M$9.93M$8.20M$8.87M$7.34M$6.83M$6.53M$6.00M$5.64M$4.63M$8.72M
    Operating Income$-61,482,000$-46,533,000$-69,541,000$-40,288,000$-34,927,000$-33,177,000$-31,916,000$-29,900,000$-22,204,000$-17,844,000$-12,956,000$-15,759,000
    Interest Income$11.54M$6.26M$5.27M$3.66M$3.40M$3.79M$3.99M$4.45M$4.71M$4.22M$2.44M$1.03M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-50,215,000$-40,532,000$-64,713,000$-36,992,000$-31,629,000$-29,511,000$-28,440,000$-25,174,000$-17,607,000$-13,748,000$-10,563,000$-14,763,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-50,215,000$-40,834,000$-64,432,000$-36,765,000$-31,629,000$-29,511,000$-28,440,000$-25,174,000$-17,607,000$-13,748,000$-10,563,000$-14,763,000
    EBITDA$-67,304,000$-47,939,000$-70,706,000$-42,862,000$-36,063,000$-35,068,000$-35,237,000$-31,844,000$-22,626,000$-18,381,000$-13,431,000$-16,033,000
    EBIT$-61,757,000$-46,797,000$-69,948,000$-40,650,000$-35,064,000$-33,302,000$-32,578,000$-29,619,000$-22,315,000$-17,970,000$-13,007,000$-15,790,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNTH

    News

    Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright

    HC Wainwright has reaffirmed a "Buy" rating for Dianthus Therapeutics (NASDAQ:DNTH) with a $158 price target, indicating a potential upside of 112% from its previous closing price. Despite this positive outlook...

    MarketBeat•10/15/26•Somewhat-Bullish

    HC Wainwright & Co. reiterates Buy rating on Dianthus Therapeutics, $158 price target

    HC Wainwright & Co. has reiterated its Buy rating on Dianthus Therapeutics (DNTH) with a price target of $158.00...

    TradingView•10/15/26•Bullish

    Dianthus Therapeutics, Inc. (DNTH) Options Chain

    This article provides the options chain for Dianthus Therapeutics, Inc. (DNTH). As of the provided data, there are no calls or puts listed as "In The Money" for the contract with a last trade date of February 19...

    Yahoo! Finance Canada•10/14/26•Neutral

    Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma

    Dianthus Therapeutics, Inc. has been selected for Fortune's 2026 Best Workplaces in BioPharma List, marking its first appearance and ranking among the top small- and medium-sized companies. The company was recognized...

    The Manila Times•10/13/26•Bullish

    Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion

    Dianthus Therapeutics (NASDAQ:DNTH) has been recognized on Fortune's 2026 Best Workplaces in BioPharma list for the first time...

    Yahoo Finance•10/13/26•Somewhat-Bullish

    DNTH Valuation and Fair Value

    P/E
    -18.0x
    P/FCF
    -26.8x
    P/B
    3.6x
    See GNG's fair value

    DNTH Profitability: Margins, ROIC and FCF

    Operating margin
    -8079.0%
    Net margin
    0.0%
    ROE
    -26.1%
    FCF margin
    -9529.3%
    FCF yield
    -3.7%

    DNTH Competitors

    CompanyTicker
    LivaNova PLCLIVN
    ICU Medical IncICUI
    Heartflow, Inc. Common StockHTFL
    Regencell Bioscience Holdings LtdRGC
    Integer Holdings CorpITGR
    Premier IncPINC
    Diversified Healthcare TrustDHCNL
    Adaptive Biotechnologies CorpADPT

    Sector: Healthcare

    DNTH Analyst Ratings

    Consensus
    Buy
    Analysts
    17
    Strong Buy
    1
    Buy
    16
    Hold
    0
    Sell
    0
    Strong Sell
    0

    DNTH Bull Case vs Bear Case

    Bull case

    • DNTH grew quarterly revenue 294.3% year over year.
    • 100.0% of DNTH's analyst ratings are Buy or Strong Buy.

    Bear case

    • DNTH beat EPS estimates in 25.0% of its last 8 reported quarters.

    DNTH Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -9.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.95
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About DNTH

    Does DNTH pay dividends?

    Dianthus Therapeutics Inc. (DNTH) does not currently pay a regular dividend.

    What is DNTH's market cap?

    Dianthus Therapeutics Inc. (DNTH) has a market capitalization of $4.18B with a current stock price of $74.53.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In